AUTL: Autolus Therapeutics plc Stocks News on June 27, 2025

$Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)$

AUTL

GlobeNewswire

a month ago

Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

AUTL

Insider Monkey

a month ago

Autolus Therapeutics plc (AUTL): Analysts See 697% Upside Potential

Promising Penny Stocks To Watch In May 2025

AUTL

Simply Wall St.

a month ago

Promising Penny Stocks To Watch In May 2025

Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress

AUTL

GlobeNewswire

a month ago

Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress

Autolus Therapeutics First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

AUTL

Simply Wall St.

2 months ago

Autolus Therapeutics First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

AUTL

GuruFocus.com

2 months ago

Autolus Therapeutics PLC (AUTL) Q1 2025 Earnings Call Highlights: Strong US Launch and ...

Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

AUTL

GlobeNewswire

2 months ago

Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

AUTL

GuruFocus.com

2 months ago

Autolus Therapeutics PLC (AUTL) Q1 2025 Earnings Report Preview: What to Expect

Autolus Therapeutics confirms license of Aucatzyl issued by U.K. MHRA

AUTL

TipRanks

2 months ago

Autolus Therapeutics confirms license of Aucatzyl issued by U.K. MHRA

AUTL

MT Newswires

2 months ago

Autolus Gets Conditional Marketing Authorization for Aucatzyl to Treat Relapsed Leukemia

$Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)$

AUTL

GlobeNewswire

2 months ago

Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)

Autolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor Event

AUTL

GlobeNewswire

2 months ago

Autolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor Event

Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

AUTL

GlobeNewswire

2 months ago

Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

AUTL

Simply Wall St.

2 months ago

April 2025's Top Penny Stocks To Watch

Autolus Therapeutics price target lowered to $10 from $11 at Truist

AUTL

TipRanks

3 months ago

Autolus Therapeutics price target lowered to $10 from $11 at Truist

Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

AUTL

GlobeNewswire

3 months ago

Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025

AUTL

GlobeNewswire

3 months ago

Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025

AUTL

MT Newswires

3 months ago

Truist Adjusts Price Target on Autolus Therapeutics to $10 From $11, Maintains Buy Rating

AUTL

GuruFocus.com

3 months ago

What To Expect From Autolus Therapeutics PLC (AUTL) Q4 2024 Earnings

AUTL

GuruFocus.com

3 months ago

Autolus Therapeutics PLC (AUTL) Q4 2024 Earnings Call Highlights: Financial Growth Amid Rising Costs

AUTL

Thomson Reuters StreetEvents

3 months ago

Q4 2024 Autolus Therapeutics PLC Earnings Call

Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

AUTL

GlobeNewswire

3 months ago

Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Autolus Therapeutics to Report Fourth Quarter 2024 Financial Results and Host Conference Call on March 20, 2025

AUTL

GlobeNewswire

4 months ago

Autolus Therapeutics to Report Fourth Quarter 2024 Financial Results and Host Conference Call on March 20, 2025

AUTL

Insider Monkey

4 months ago

Is Autolus Therapeutics plc (AUTL) the Best UK Growth Stock to Buy Now?

AUTL

GlobeNewswire

4 months ago

Autolus Therapeutics to Participate in Upcoming Investor Conferences

Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings

AUTL

GlobeNewswire

5 months ago

Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings

Autolus Therapeutics Provides Business Updates and 2025 Overview

AUTL

GlobeNewswire

5 months ago

Autolus Therapeutics Provides Business Updates and 2025 Overview

AUTL

Insider Monkey

6 months ago

Why Autolus Therapeutics (AUTL) Is One of the Best Biotech Penny Stocks to Invest in Now?

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024

AUTL

GlobeNewswire

7 months ago

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024

AUTL

Insider Monkey

7 months ago

Autolus Therapeutics plc (AUTL): A Bull Case Theory

Autolus Therapeutics Announces Publication of Data from the FELIX study of obe-cel in r/r Adult B-ALL Patients in The New England Journal of Medicine

AUTL

GlobeNewswire

7 months ago

Autolus Therapeutics Announces Publication of Data from the FELIX study of obe-cel in r/r Adult B-ALL Patients in The New England Journal of Medicine

Autolus Therapeutics upgraded to Buy from Neutral at Goldman Sachs

AUTL

TipRanks

7 months ago

Autolus Therapeutics upgraded to Buy from Neutral at Goldman Sachs

AUTL

MT Newswires

7 months ago

Goldman Sachs Upgrades Autolus Therapeutics to Buy From Neutral, Adjusts Price Target to $7.60 From $7

Autolus Therapeutics Third Quarter 2024 Earnings: US$0.31 loss per share (vs US$0.26 loss in 3Q 2023)

AUTL

Simply Wall St.

7 months ago

Autolus Therapeutics Third Quarter 2024 Earnings: US$0.31 loss per share (vs US$0.26 loss in 3Q 2023)

AUTL

MT Newswires

7 months ago

Redburn Atlantic Upgrades Autolus Therapeutics to Buy From Neutral, Price Target is $13

AUTL

GuruFocus.com

7 months ago

Syncona Ltd (LSE:SYNC) Half Year 2025 Earnings Call Highlights: Navigating Market Challenges ...

AUTL

GuruFocus.com

7 months ago

Autolus Therapeutics PLC (AUTL) Q3 2024 Earnings Call Highlights: Strategic Advances and ...

AUTL

Thomson Reuters StreetEvents

7 months ago

Q3 2024 Autolus Therapeutics PLC Earnings Call

Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates

AUTL

GlobeNewswire

7 months ago

Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates

These Stocks Moved the Most Today: Tesla, DJT, Coinbase, MARA, Cigna, Humana, AbbVie, Super Micro, and More

AUTL

Barrons.com

8 months ago

These Stocks Moved the Most Today: Tesla, DJT, Coinbase, MARA, Cigna, Humana, AbbVie, Super Micro, and More

These Stocks Are Moving the Most Today: Tesla, DJT, Coinbase, MARA, Cigna, Humana, AbbVie, Super Micro, and More

AUTL

Barrons.com

8 months ago

These Stocks Are Moving the Most Today: Tesla, DJT, Coinbase, MARA, Cigna, Humana, AbbVie, Super Micro, and More

Autolus secures FDA approval for CAR-T cell therapy use in ALL

AUTL

Pharmaceutical Technology

8 months ago

Autolus secures FDA approval for CAR-T cell therapy use in ALL

AUTL

MT Newswires

8 months ago

Sector Update: Health Care Stocks Mixed Premarket Monday

AUTL

GuruFocus.com

8 months ago

What To Expect From Autolus Therapeutics PLC (AUTL) Q3 2024 Earnings

FDA approves new CAR-T competitor to Gilead’s Tecartus

AUTL

BioPharma Dive

8 months ago

FDA approves new CAR-T competitor to Gilead’s Tecartus

AUTL

MT Newswires

8 months ago

Autolus Therapeutics' Leukemia Treatment Receives US FDA Approval

$Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)$

AUTL

GlobeNewswire

8 months ago

Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 in One Oral Presentation and Three Poster Presentations

AUTL

GlobeNewswire

8 months ago

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 in One Oral Presentation and Three Poster Presentations

AUTL

Simply Wall St.

8 months ago

Further weakness as Autolus Therapeutics (NASDAQ:AUTL) drops 21% this week, taking five-year losses to 71%

Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

AUTL

GlobeNewswire

8 months ago

Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

AUTL

Insider Monkey

8 months ago

Autolus Therapeutics (AUTL): High-Growth UK Stock in Cancer Therapy

Autolus Therapeutics Presents Clinical Data Update at the 2024 Lymphoma, Leukemia & Myeloma Congress

AUTL

GlobeNewswire

8 months ago

Autolus Therapeutics Presents Clinical Data Update at the 2024 Lymphoma, Leukemia & Myeloma Congress

AUTL

Insider Monkey

8 months ago

Why Autolus Therapeutics plc (AUTL) is the Penny Stock with the Biggest Upside Potential According to Analysts

AUTL

GuruFocus.com

9 months ago

Autolus Therapeutics PLC (AUTL) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ...

Autolus Therapeutics announces appointment of Matthias Will, M.D. as Chief Development Officer

AUTL

GlobeNewswire

9 months ago

Autolus Therapeutics announces appointment of Matthias Will, M.D. as Chief Development Officer

AUTL

MT Newswires

9 months ago

Autolus Therapeutics to Amend Lease at Nucleus Manufacturing Facility in UK

AUTL

Insider Monkey

9 months ago

Autolus Therapeutics PLC (AUTL): Fast-Growing Penny Stock To Consider

AUTL

Insider Monkey

10 months ago

Autolus Therapeutics plc (AUTL): The Best Multibagger Penny Stock of 2025?

Autolus Therapeutics Presents Clinical Data Update at the Society of Hematologic Oncology (SOHO) Annual Meeting 2024

AUTL

GlobeNewswire

10 months ago

Autolus Therapeutics Presents Clinical Data Update at the Society of Hematologic Oncology (SOHO) Annual Meeting 2024

AUTL

Simply Wall St.

10 months ago

Autolus Therapeutics (NASDAQ:AUTL) Is In A Good Position To Deliver On Growth Plans

AUTL

MT Newswires

a year ago

Autolus Therapeutics Q2 Loss Narrows; Shares Fall

Autolus Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates

AUTL

GlobeNewswire

a year ago

Autolus Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates

Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024

AUTL

GlobeNewswire

a year ago

Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024

$Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress$

AUTL

GlobeNewswire

a year ago

Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress

Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO

AUTL

GlobeNewswire

a year ago

Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO

AUTL

Thomson Reuters StreetEvents

a year ago

Q1 2024 Autolus Therapeutics PLC Earnings Call

AUTL

MT Newswires

a year ago

Autolus Therapeutics' Q1 Loss Widens, Licensing Revenue Rises

Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

AUTL

GlobeNewswire

a year ago

Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

$Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress$

AUTL

GlobeNewswire

a year ago

Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress

AUTL

MT Newswires

a year ago

Autolus Therapeutics Announces Delay of Q1 Earnings Release

Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call

AUTL

GlobeNewswire

a year ago

Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call

AUTL

Simply Wall St.

a year ago

Recent 13% pullback isn't enough to hurt long-term Autolus Therapeutics (NASDAQ:AUTL) shareholders, they're still up 157% over 1 year

Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO

AUTL

GlobeNewswire

a year ago

Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO

Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

AUTL

GlobeNewswire

a year ago

Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

$Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)$